Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

ClinicalTrials.gov ID: NCT05432804

Public ClinicalTrials.gov record NCT05432804. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 1, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozolomide) in treating patients with glioblastoma that has come back (recurrent). Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Giving selinexor in combination with usual chemotherapy (temozolomide) may shrink or stabilize the tumor better than the usual chemotherapy with temozolomide alone in patients with recurrent glioblastoma.

Study identification

NCT ID
NCT05432804
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
97 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 19, 2023
Primary completion
Jun 29, 2027
Completion
Jun 29, 2027
Last update posted
Aug 25, 2026

2023 – 2027

United States locations

U.S. sites
36
U.S. states
17
U.S. cities
31
Facility City State ZIP Site status
Mayo Clinic Hospital in Arizona Phoenix Arizona 85054 Recruiting
City of Hope Comprehensive Cancer Center Duarte California 91010 Recruiting
UC San Diego Moores Cancer Center La Jolla California 92093 Recruiting
Keck Medicine of USC Koreatown Los Angeles California 90020 Suspended
Los Angeles General Medical Center Los Angeles California 90033 Suspended
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 Suspended
University of California Davis Comprehensive Cancer Center Sacramento California 95817 Recruiting
UCHealth University of Colorado Hospital Aurora Colorado 80045 Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables Florida 33146 Recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach Florida 33442 Recruiting
Mayo Clinic in Florida Jacksonville Florida 32224-9980 Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136 Recruiting
Moffitt Cancer Center Tampa Florida 33612 Recruiting
Emory University Hospital Midtown Atlanta Georgia 30308 Recruiting
Emory University Hospital/Winship Cancer Institute Atlanta Georgia 30322 Recruiting
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637 Recruiting
University of Chicago Medicine-Orland Park Orland Park Illinois 60462 Recruiting
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 Recruiting
Mayo Clinic in Rochester Rochester Minnesota 55905 Recruiting
Cooperman Barnabas Medical Center Livingston New Jersey 07039 Recruiting
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 Recruiting
Rutgers New Jersey Medical School Newark New Jersey 07101 Suspended
Roswell Park Cancer Institute Buffalo New York 14263 Active, not recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016 Recruiting
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032 Suspended
Wake Forest University Health Sciences Winston-Salem North Carolina 27157 Recruiting
University of Cincinnati Cancer Center-UC Medical Center Cincinnati Ohio 45219 Recruiting
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 Recruiting
University of Cincinnati Cancer Center-West Chester West Chester Ohio 45069 Recruiting
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 Recruiting
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 Recruiting
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 Active, not recruiting
University of Virginia Cancer Center Charlottesville Virginia 22908 Active, not recruiting
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298 Active, not recruiting
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison Wisconsin 53718 Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital Madison Wisconsin 53792 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05432804, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 25, 2026 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05432804 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →